Blood Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Tumor angiogenesis is limited by promyelocytic leukemia tumor suppressor
October 5th, 2006
Tumor angiogenesis is limited by promyelocytic leukemia (PML) tumor suppressor. "Loss of the PML tumour suppressor has been observed in several human cancers. The tumour-suppressive function of PML has been attributed to its ability to induce growth arrest, cellular senescence and apoptosis," researchers in the United States report. "Here we identify PML as a critical inhibitor of neoangiogenesis (the formation of new blood vessels) in vivo, in both ischaemic and neoplastic conditions, through the control of protein translation. We demonstrate that in hypoxic conditions PML acts as a negative regulator of the synthesis rate of hypoxia-inducible...
Source: Blood Weekly (2006-10-05)
|
